CAR-T Cell Therapy in First Line for High Risk Diffuse Large B-Cell Lymphoma: Review of Efficacy and Cost-Effectiveness Against Standard of Care Chemo-Immunotherapy-Reference-Cited by-同舟云学术

CAR-T Cell Therapy in First Line for High Risk Diffuse Large B-Cell Lymphoma: Review of Efficacy and Cost-Effectiveness Against Standard of Care Chemo-Immunotherapy

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:12052-12054
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Akbar Usman Ali¹,Rashid Zaraq²,Rehman Zarlish³,Alam Shehzad⁴,Altaf Zooha⁵,Anwar Rana Usman⁶,Khan Adil⁶,Wakeel Jafir⁶,Farooq Saad⁷,Khan Muhammad Haris⁸,Safi Danish⁹,Inayat Arslan¹⁰,Safi Salah Ud Din⁹

Affiliation:

1. 1Department of Internal Medicine, Northwell Health, New York, NY

2. 2LRH, Peshawar, Pakistan

3. 3Hayatabad Medical Complex, PESHWAR, PAK

4. 4Khyber Teaching Hospital, Peshawar, Pakistan

5. 5Eastern Virginia Medical School, Norfolk, VA

6. 6University of Louisville, Louisville, KY

7. 7Nishtar Medical University, Multan, Pakistan

8. 8Divison of Infectious Diseases, University of Louisiana, Shreveport, LA

9. 9West Virginia University, Morgantown, WV

10. 10University at Buffalo, Buffalo, NY

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review;European Journal of Pharmacology;2024-07

2. Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults;European Journal of Haematology;2024-06-18